Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
To read the full story
Related Article
- Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
- Japan to Revamp Scheme for Drug Maker’s Reporting of Supply Concerns in April
February 7, 2024
- Panel Snubs Outline of Guidelines for Supply Info Reporting, Production Requests Due to Lack of Explanations
December 12, 2023
- MHLW Proposes Posting Reported Drug Supply Concerns on Its Website
November 22, 2023
REGULATORY
- Pharma Industry Wants “Internationally Harmonized” Rules under PMD Act
May 20, 2024
- Novartis’ Fabhalta, Novo’s Awiqli, and More Up for PAFSC Review on May 31
May 20, 2024
- Expand Mixed-Billing Scheme, Use of Private Payers: LDP Healthcare Reform Team
May 20, 2024
- Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
- Japan to Simplify Keytruda’s Optimal Use Guidelines for 4 Indications
May 17, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…